Mesoblast Limited (MESO)
NASDAQ
MESO price, last 12 months
Key stats
- Previous close
- $11.64
- Open
- $11.51
- Day range
- $11.02 – $11.56
- 52-week range
- $10.87 – $21.50
- Volume
- 262.6K
- Avg volume (20 days)
- 236.4K
- Market cap
- $1.7B
Performance
Technicals and fundamentals
About Mesoblast Limited
Mesoblast Ltd is a commercial-stage biotechnology company engaged in developing and commercializing allogeneic (off-the-shelf) cellular medicines for severe inflammatory conditions. Its commercial product, Ryoncil (remestemcel-L-rknd), is FDA-approved for steroid-refractory acute graft-versus-host disease in pediatric patients. The company is also developing Ryoncil for additional inflammatory indications. Its rexlemestrocel-L platform is being developed for chronic low back pain associated with degenerative disc disease and chronic heart failure. The company operates as a single segment focused on its allogeneic cellular medicines platform.
- Listed on
- NASDAQ
- Market cap
- $1.7B